Table 3.
The average release rates of TAF from implants fabricated with PCL MW blends. The percent purity of TAF was determined at the conclusion of the in vitro studies (i.e., day 136). The approximate quantity of drug payload for implants comprising each PCL formulation. Implants were gamma-irradiated before initiating the in vitro study. All samples were performed in triplicate.
| Formulation | Approximate TAF Payload (mg) | Average Release Rate (mg/day, 40 mm Implant) | % Purity of TAF at Day 136 |
|---|---|---|---|
| PC-12/PC-17 25/75 | 114 ± 5 | 0.33 ± 0.01 | 91.2 ± 3.1 |
| PC-12/PC-17 50/50 | 116 ± 2 | 0.23 ± 0.04 | 96.2 ± 0.8 |
| PC-12/PC-17 75/25 | 116 ± 4 | 0.18 ± 0.01 | 94.8 ± 0.7 |
| PC-08/PC-12 25/75 | 113 ± 2 | 0.10 ± 0.01 | 96.9 ± 0.1 |
| PC-08/PC-12 50/50 | 112 ± 2 | 0.09 ± 0.01 | 96.4 ± 0.4 |
| PC-08/PC-12 75/25 | 112 ± 2 | 0.06 ± 0.01 | 96.7 ± 0.1 |
| PC-08/PC-17 25/75 | 115 ± 4 | 0.24 ± 0.02 | 95.2 ± 0.4 |
| PC-08/PC-17 50/50 | 108 ± 3 | 0.16 ± 0.02 | 93.3 ± 1.1 |
| PC-08/PC-17 75/25 | 119 ± 3 | 0.09 ± 0.01 | 95.1 ± 0.3 |